BCG 008
Alternative Names: BCG-008Latest Information Update: 31 May 2023
At a glance
- Originator Beijing Biocytogen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Siglec-15 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2023 BCG 008 is available for licensing as of 31 May 2023. http://en.biocytogen.com.cn/about-us/cooperation.html
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 20 Jul 2022 Preclinical trials in Solid tumours in China (Parenteral) (Beijing Biocytogen website, July 2022)